Thermo Fisher Scientific Recognized as Top Vaccine CRO and Bioprocessing Supplier at Vaccines World Asia Congress
WILMINGTON, N.C. (December 12, 2023) – Thermo Fisher Scientific Inc., the world leader in serving science, has been named “Best Vaccine CRO of the Year” and “Best Vaccine Supplier: Bioprocessing” at the Asia-Pacific Vaccine Excellence Awards 2023.
Thermo Fisher was recognized for its contribution to helping customers develop safe and effective vaccines and enabling vaccine manufacturers within Asia-Pacific to innovate, optimize processes and uphold a high level of quality and safety in vaccine development and manufacturing.
Thermo Fisher leaders accepted the two awards during a ceremony at the Vaccine World Asia Congress held in Singapore. The annual event, which attracts hundreds of representatives from Asia’s top vaccine and supply chain companies, brings together global partners and regional stakeholders to leverage partnership opportunities, discuss technological advancements and spearhead scientific innovation.
Thermo Fisher’s PPD clinical research business’ offers vaccine development services across six continents, with local expertise in all regions, including Asia-Pacific. The business utilizes development capabilities and expertise in vaccine development to help customers attend to the unique needs of vaccine trials and accelerate development with proven solutions and dedicated resources. Services can be tailored across trial phases, for localized or global studies, for biotech and large pharmaceutical companies and not-for-profit and governmental programs.
“We are honored to be recognized as a world leader for the third consecutive year for supporting our customers’ vaccines research in Asia-Pacific,” said Les Enterline, vaccines global therapeutic unit head, clinical research, Thermo Fisher Scientific. “Through our expansive global footprint, development capabilities and expertise, we are able to serve our customers and their vaccine development with dedicated resources and quality delivery.”
Thermo Fisher’s bioproduction business provides the technology, materials and services for customers to develop and produce life-changing medicines efficiently, sustainably and cost effectively. Customers depend on Thermo Fisher’s technologies, customizable solutions and scientific expertise to scale efficiently and effectively, bringing medicines to patients faster than ever before. Thermo Fisher’s bioprocessing products are integrated into hundreds of commercial drugs and thousands of clinical pipelines.
“We are driven to help customers enhance their bioprocessing workflows so they can deliver effective and safe vaccines,” said Jenny Tan, senior director, APAC, Thermo Fisher Scientific. “We are proud that our unwavering commitment to deliver state-of-the-art technologies to vaccines manufacturers worldwide and the tremendous impact our colleagues are making on global health have been recognized with this distinction.”
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Media Contact Information: